Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI)

a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

EURO-SKI Investigators

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Alkuperäiskielienglanti
LehtiLancet Oncology
Vuosikerta19
Numero6
Sivut747-757
Sivumäärä11
ISSN1470-2045
DOI - pysyväislinkit
TilaJulkaistu - kesäkuuta 2018
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3122 Syöpätaudit

Lainaa tätä

@article{13810d4eb25245d3899a9677dba88a6a,
title = "Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial",
keywords = "MAJOR MOLECULAR RESPONSE, TREATMENT-FREE REMISSION, IMATINIB DISCONTINUATION, WITHDRAWAL SYNDROME, PHASE-2 TRIAL, FOLLOW-UP, SURVIVAL, DASATINIB, NILOTINIB, DISEASE, 3122 Cancers",
author = "{EURO-SKI Investigators} and Susanne Saussele and Johan Richter and Joelle Guilhot and Gruber, {Franz X.} and Henrik Hjorth-Hansen and Antonio Almeida and Janssen, {Jeroen J. W. M.} and Jiri Mayer and Perttu Koskenvesa and Panayiotis Panayiotidis and Ulla Olsson-Stromberg and Joaquin Martinez-Lopez and Philippe Rousselot and Hanne Vestergaard and Hans Ehrencrona and Veli Kairisto and Polakova, {Katerina Machova} and Mueller, {Martin C.} and Satu Mustjoki and Berger, {Marc G.} and Alice Fabarius and Wolf-Karsten Hofmann and Andreas Hochhaus and Markus Pfirrmann and Francois-Xavier Mahon",
year = "2018",
month = "6",
doi = "10.1016/S1470-2045(18)30192-X",
language = "English",
volume = "19",
pages = "747--757",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",
number = "6",

}

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. / EURO-SKI Investigators.

julkaisussa: Lancet Oncology, Vuosikerta 19, Nro 6, 06.2018, s. 747-757.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI)

T2 - a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

AU - EURO-SKI Investigators

AU - Saussele, Susanne

AU - Richter, Johan

AU - Guilhot, Joelle

AU - Gruber, Franz X.

AU - Hjorth-Hansen, Henrik

AU - Almeida, Antonio

AU - Janssen, Jeroen J. W. M.

AU - Mayer, Jiri

AU - Koskenvesa, Perttu

AU - Panayiotidis, Panayiotis

AU - Olsson-Stromberg, Ulla

AU - Martinez-Lopez, Joaquin

AU - Rousselot, Philippe

AU - Vestergaard, Hanne

AU - Ehrencrona, Hans

AU - Kairisto, Veli

AU - Polakova, Katerina Machova

AU - Mueller, Martin C.

AU - Mustjoki, Satu

AU - Berger, Marc G.

AU - Fabarius, Alice

AU - Hofmann, Wolf-Karsten

AU - Hochhaus, Andreas

AU - Pfirrmann, Markus

AU - Mahon, Francois-Xavier

PY - 2018/6

Y1 - 2018/6

KW - MAJOR MOLECULAR RESPONSE

KW - TREATMENT-FREE REMISSION

KW - IMATINIB DISCONTINUATION

KW - WITHDRAWAL SYNDROME

KW - PHASE-2 TRIAL

KW - FOLLOW-UP

KW - SURVIVAL

KW - DASATINIB

KW - NILOTINIB

KW - DISEASE

KW - 3122 Cancers

U2 - 10.1016/S1470-2045(18)30192-X

DO - 10.1016/S1470-2045(18)30192-X

M3 - Article

VL - 19

SP - 747

EP - 757

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 6

ER -